June 15, 2024

Alpha Emitter Market Size to Attain USD 1,488.02 Million By 2033

The global alpha emitter market size was valued at USD 581.6 million in 2023 and is expected to reach around USD 1,488.02 million by 2033, notable at a CAGR of 9.90% from 2024 to 2033.

Key Takeaways

  • North America contributed more than 44% of market share in 2023.
  • Asia-Pacific is estimated to expand at the fastest CAGR between 2024 and 2033.
  • By type of radionuclide, the actinium (Ac-225) segment has held the largest market share of 38% in 2023.
  • By type of radionuclide, the radium (Ra-223) segment is anticipated to grow at a remarkable CAGR of 10.16% between 2024 and 2033.
  • By application, the bone metastases segment generated over 36% of the market share in 2023.
  • By application, the prostate cancer segment is expected to expand at the fastest CAGR over the projected period.
  • By source, the natural sources segment generated over 54% of the market share in 2023.
  • By source, the artificially produced sources segment is expected to expand at the fastest CAGR over the projected period.

Alpha Emitter Market Size 2024 To 2033

The Alpha Emitter market is experiencing robust growth, driven by several key factors that contribute to its expansion and prominence in various industries. These growth factors are instrumental in shaping the market landscape and influencing the demand for alpha emitters across diverse applications.

Get a Sample: https://www.precedenceresearch.com/sample/3690

Growth Factors

One of the primary drivers fueling the growth of the Alpha Emitter market is the increasing adoption of alpha emitters in medical applications, particularly in cancer treatment. The unique properties of alpha emitters make them effective in targeted cancer therapies, leading to a rising demand within the healthcare sector. Additionally, advancements in nuclear medicine and radiopharmaceutical research further contribute to the market’s positive trajectory.

Alpha Emitter Market Scope

Report CoverageDetails
Growth Rate from 2024 to 2033CAGR of 9.90%
Global Market Size in 2023USD 581.6 Million
Global Market Size by 2033USD 1,488.02 Million
U.S.  Market Size in 2023USD 179.13 Million
U.S. Market Size by 2033USD 466.72 Million
Base Year2023
Forecast Period2024 To 2033
Segments CoveredBy Type of Radionuclide, By Application, By Source
Regions CoveredNorth America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Read More: Metaverse in E-commerce Market Size to Grow USD 936.28 Bn By 2033

Alpha Emitter Market Dynamics

Drivers

The market is propelled by technological advancements and innovations in alpha emitter production and application. Ongoing research and development efforts are leading to the creation of novel alpha emitters with enhanced properties, widening their scope in various industrial applications. The expanding use of alpha emitters in oil and gas exploration and certain manufacturing processes is another significant driver fostering market growth.

Restraints

Despite the promising growth, the Alpha Emitter market faces certain restraints that need consideration. Regulatory challenges and concerns regarding the safe handling and disposal of alpha-emitting materials pose obstacles to market expansion. Stricter regulations and compliance standards impact the market dynamics, requiring industry players to invest in stringent safety measures.

Opportunities

Amid challenges, the market presents lucrative opportunities driven by the increasing awareness of alpha emitters’ potential benefits. Opportunities lie in educating end-users about the advantages of alpha emitters in specific applications, fostering a greater understanding and acceptance. Additionally, expanding research and development activities can unlock new opportunities for alpha emitter applications in emerging sectors.

Region Snapshot

Geographically, the Alpha Emitter market exhibits a varied landscape with regional nuances influencing market dynamics. North America holds a significant share, driven by a strong presence of key market players and substantial investments in healthcare and research. The Asia-Pacific region is emerging as a key player, with growing industrialization and increasing healthcare expenditures contributing to market growth. Europe, too, is a noteworthy market player with a focus on sustainable practices in nuclear technologies.

Reasons to Purchase this Report:

  • Comprehensive market segmentation analysis incorporating qualitative and quantitative research, considering the impact of economic and policy factors.
  • In-depth regional and country-level analysis, examining the demand and supply dynamics that influence market growth.
  • Market size in USD million and volume in million units provided for each segment and sub-segment.
  • Detailed competitive landscape, including market share of major players, recent projects, and strategies implemented over the past five years.
  • Comprehensive company profiles encompassing product offerings, key financial information, recent developments, SWOT analysis, and employed strategies by major market players.

Recent Developments

  • In November 2022, NorthStar Medical Radioisotopes, a pharmaceutical company, and IBA Worldwide, a medical technology firm, unveiled a new agreement. NorthStar will acquire its third Rhodotron TT300 HE electron beam accelerator from IBA. This accelerator plays a crucial role in producing no-carrier added actinium-225 (Ac225), a vital therapeutic radioisotope facing limited supply and lacking commercial-scale production technology.
  • In January 2022, biotechnology companies RadioMedix and Orano Med announced the commencement of a Phase II clinical trial for AlphaMedix. The trial, initiated on December 21, 2021, assesses the safety and efficacy of 212Pb-DOTAMTATE (AlphaMedix) in Peptide Receptor Radionuclide Therapy (PRRT) for patients with somatostatin receptor-expressing neuroendocrine tumors (NET) who are new to treatment.
  • In June 2022, medical technology company Alpha Tau Medical Ltd. received approval from the U.S. Food and Drug Administration (FDA) for its Investigational Device Exemption (IDE) application. This green light allows the initiation of a multi-center pivotal study using Alpha DaRT for the treatment of recurrent cutaneous Squamous Cell Carcinoma (SCC).

Alpha Emitter Market Companies

  • Alpha Tau Medical Ltd.
  • NorthStar Medical Radioisotopes
  • IBA Worldwide
  • RadioMedix
  • Orano Med
  • Bayer AG
  • Novartis International AG
  • Actinium Pharmaceuticals, Inc.
  • Fusion Pharmaceuticals Inc.
  • Eckert & Ziegler
  • Telix Pharmaceuticals Limited
  • Curium Pharma
  • AAA (Advanced Accelerator Applications)
  • Isotopen Technologien München AG (ITM)
  • Nordion (Canada) Inc.

Segments Covered in the Report

By Type of Radionuclide

  • Radium (Ra-223)
  • Actinium (Ac-225)
  • Lead (Pb-212)
  • Astatine-211
  • Bismuth-213
  • Others

By Application

  • Bone Metastases
  • Prostate Cancer
  • Neuroendocrine Tumors
  • Ovarian Cancer
  • Others

By Source

  • Natural Sources (Uranium-238, Radium-226)
  • Artificially Produced Sources (Plutonium, Americium, Curium, Californium)
  • Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Alpha Emitter Market 

5.1. COVID-19 Landscape: Alpha Emitter Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Alpha Emitter Market, By Type of Radionuclide

8.1. Alpha Emitter Market, by Type of Radionuclide, 2024-2033

8.1.1 Radium (Ra-223)

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Actinium (Ac-225)

8.1.2.1. Market Revenue and Forecast (2021-2033)

8.1.3. Lead (Pb-212)

8.1.3.1. Market Revenue and Forecast (2021-2033)

8.1.4. Astatine-211

8.1.4.1. Market Revenue and Forecast (2021-2033)

8.1.5. Bismuth-213

8.1.5.1. Market Revenue and Forecast (2021-2033)

8.1.6. Others

8.1.6.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Alpha Emitter Market, By Application

9.1. Alpha Emitter Market, by Application, 2024-2033

9.1.1. Bone Metastases

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Prostate Cancer

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Neuroendocrine Tumors

9.1.3.1. Market Revenue and Forecast (2021-2033)

9.1.4. Ovarian Cancer

9.1.4.1. Market Revenue and Forecast (2021-2033)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Alpha Emitter Market, By Source 

10.1. Alpha Emitter Market, by Source, 2024-2033

10.1.1. Natural Sources (Uranium-238, Radium-226)

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Artificially Produced Sources (Plutonium, Americium, Curium, Californium)

10.1.2.1. Market Revenue and Forecast (2021-2033)

10.1.3. Others

10.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 11. Global Alpha Emitter Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.1.2. Market Revenue and Forecast, by Application (2021-2033)

11.1.3. Market Revenue and Forecast, by Source (2021-2033)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.1.4.2. Market Revenue and Forecast, by Application (2021-2033)

11.1.4.3. Market Revenue and Forecast, by Source (2021-2033)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.1.5.2. Market Revenue and Forecast, by Application (2021-2033)

11.1.5.3. Market Revenue and Forecast, by Source (2021-2033)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.2.2. Market Revenue and Forecast, by Application (2021-2033)

11.2.3. Market Revenue and Forecast, by Source (2021-2033)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.2.4.2. Market Revenue and Forecast, by Application (2021-2033)

11.2.4.3. Market Revenue and Forecast, by Source (2021-2033)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.2.5.2. Market Revenue and Forecast, by Application (2021-2033)

11.2.5.3. Market Revenue and Forecast, by Source (2021-2033)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.2.6.2. Market Revenue and Forecast, by Application (2021-2033)

11.2.6.3. Market Revenue and Forecast, by Source (2021-2033)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.2.7.2. Market Revenue and Forecast, by Application (2021-2033)

11.2.7.3. Market Revenue and Forecast, by Source (2021-2033)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.3.2. Market Revenue and Forecast, by Application (2021-2033)

11.3.3. Market Revenue and Forecast, by Source (2021-2033)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.3.4.2. Market Revenue and Forecast, by Application (2021-2033)

11.3.4.3. Market Revenue and Forecast, by Source (2021-2033)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.3.5.2. Market Revenue and Forecast, by Application (2021-2033)

11.3.5.3. Market Revenue and Forecast, by Source (2021-2033)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.3.6.2. Market Revenue and Forecast, by Application (2021-2033)

11.3.6.3. Market Revenue and Forecast, by Source (2021-2033)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.3.7.2. Market Revenue and Forecast, by Application (2021-2033)

11.3.7.3. Market Revenue and Forecast, by Source (2021-2033)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.4.2. Market Revenue and Forecast, by Application (2021-2033)

11.4.3. Market Revenue and Forecast, by Source (2021-2033)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.4.4.2. Market Revenue and Forecast, by Application (2021-2033)

11.4.4.3. Market Revenue and Forecast, by Source (2021-2033)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.4.5.2. Market Revenue and Forecast, by Application (2021-2033)

11.4.5.3. Market Revenue and Forecast, by Source (2021-2033)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.4.6.2. Market Revenue and Forecast, by Application (2021-2033)

11.4.6.3. Market Revenue and Forecast, by Source (2021-2033)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.4.7.2. Market Revenue and Forecast, by Application (2021-2033)

11.4.7.3. Market Revenue and Forecast, by Source (2021-2033)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.5.2. Market Revenue and Forecast, by Application (2021-2033)

11.5.3. Market Revenue and Forecast, by Source (2021-2033)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.5.4.2. Market Revenue and Forecast, by Application (2021-2033)

11.5.4.3. Market Revenue and Forecast, by Source (2021-2033)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.5.5.2. Market Revenue and Forecast, by Application (2021-2033)

11.5.5.3. Market Revenue and Forecast, by Source (2021-2033)

Chapter 12. Company Profiles

12.1. Alpha Tau Medical Ltd.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. NorthStar Medical Radioisotopes

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. IBA Worldwide

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. RadioMedix

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Orano Med

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Bayer AG

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Novartis International AG

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Actinium Pharmaceuticals, Inc.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Fusion Pharmaceuticals Inc.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Eckert & Ziegler

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.expresswebwire.com/

Blog: https://www.uswebwire.com/

Blog: https://www.dailytechbulletin.com/

Blog: https://www.autoindustrybulletin.com/